Combined Allergic Rhinitis andAsthma Syndrome
Conditions
Interventions
Group A:Budesonide Nasal Spray 64ug bid andBudesonide andFormoterol Fumarate Powder for Inhalation 80ug/4.5ug/suck bid
Group B:Nasaleze tid
Budesonide andFormoterol Fumarate Powder for Inhalation 80ug/4.5ug/suck bid
Group C:Lactose powder tid
Sponsors
State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
6 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Males or females aged 6 to 18 years; 2. Patient with a history of typical symptoms of perennial allergic rhinitis andallergic asthma for at least the preceding 1 year; 3. Positive allergy test for inhalatory allergens; 4. Voluntarily given written informed consent to study participation encompassing consent to data recording andverification procedures; 5. Patients are able andwilling to comply with the requirements of the study protocol; 6. Patients who have not received any study of other allergic disease treatment for one month prior to the study.
Exclusion criteria
Exclusion criteria: 1. Clinical signs of predominating nasal obstruction. The patient must be judged to be able to reach the nasal cavity with the study powder; 2. Other respiratory or chronic diseases; 3. Previous use of the study product; 4. Inability to give informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS Score for nasal symptoms;FEV1;PEF;FeNO;ACT; | — |
Secondary
| Measure | Time frame |
|---|---|
| VAS Score for eye symptom; | — |
Countries
China
Contacts
Public ContactBaoqing Sun
Outcome results
None listed